Literature DB >> 20704976

Mechanisms of bone metastasis.

G David Roodman1.   

Abstract

Extract: Cancer frequently spreads to bone, a process termed bone metastasis. Up to 70% of patients with breast cancer or prostate cancer, and 15 to 30% of patients with lung, colon, bladder or kidney cancer develop bone metastasis. Once tumors go to bone, such as in patients with breast cancer or prostate cancer, they are incurable, and only 20% of patients with breast cancer are still alive five years after they are found to have bone metastasis. It is estimated that about 350,000 people die with bone metastasis each year in the United States. Bone metastasis causes severe bone pain and can result in fractures without any injury, as well as other life-threatening conditions. There are two major types of bone metastasis, one in which bone destruction is the predominant feature and the other one in which new bone formation is predominant. Bone metastasis where bone destruction is the predominant feature is known as osteolytic, and that in which new bone formation is the primary feature is called osteoblastic. This classification for metastasis is really two extremes of a continuum because many patients can have both osteolytic and osteoblastic or mixtures of both in their bone metastasis. In fact, patients with prostate cancer who usually have bone metastasis that shows increased new bone formation also have increased bone destruction in the same lesions.

Entities:  

Year:  2004        PMID: 20704976

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  34 in total

Review 1.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

2.  [68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients.

Authors:  Jan-Carlo Janssen; Nadine Woythal; Sebastian Meißner; Vikas Prasad; Winfried Brenner; Gerd Diederichs; Bernd Hamm; Marcus R Makowski
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

3.  Vertebral and femoral bone mineral density and bone strength in prostate cancer patients assessed in phantomless PET/CT examinations.

Authors:  Benedikt J Schwaiger; David L Kopperdahl; Lorenzo Nardo; Luca Facchetti; Alexandra S Gersing; Jan Neumann; Kwang J Lee; Tony M Keaveny; Thomas M Link
Journal:  Bone       Date:  2017-04-24       Impact factor: 4.398

4.  Survival and prognostic factors in non-small cell lung cancer patients with spinal bone metastases: a retrospective analysis of 303 patients.

Authors:  H Rief; T Muley; T Bruckner; T Welzel; S Rieken; M Bischof; K Lindel; S E Combs; J Debus
Journal:  Strahlenther Onkol       Date:  2013-09-21       Impact factor: 3.621

5.  Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.

Authors:  Said M Elshafae; Wessel P Dirksen; Aylin Alasonyalilar-Demirer; Justin Breitbach; Shiyu Yuan; Noriko Kantake; Wachiraphan Supsavhad; Bardes B Hassan; Zayed Attia; Lucas B Alstadt; Thomas J Rosol
Journal:  Prostate       Date:  2020-04-29       Impact factor: 4.104

Review 6.  Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets.

Authors:  Nadia Rucci; Patrizia Sanità; Simona Delle Monache; Edoardo Alesse; Adriano Angelucci
Journal:  World J Clin Oncol       Date:  2014-08-10

7.  The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates.

Authors:  Wen Jiang; David Ulmert; Brian W Simons; Diane S Abou; Daniel L J Thorek
Journal:  Nucl Med Biol       Date:  2018-05-08       Impact factor: 2.408

8.  DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.

Authors:  Duncan R Hewett; Kate Vandyke; David M Lawrence; Natasha Friend; Jacqueline E Noll; Joel M Geoghegan; Peter I Croucher; Andrew C W Zannettino
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

Review 9.  Cell mates: paracrine and stromal targets for prostate cancer therapy.

Authors:  Pavel Sluka; Ian D Davis
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

10.  Breast cancer cells expressing cancer-associated sialyl-Tn antigen have less capacity to develop osteolytic lesions in a mouse model of skeletal colonization.

Authors:  Ryo Fujita; Hiroki Hamano; Yusuke Kameda; Ryuta Arai; Tomohiro Shimizu; Masahiro Ota; Dai Sato; Hideyuki Kobayashi; Norimasa Iwasaki; Masahiko Takahata
Journal:  Clin Exp Metastasis       Date:  2019-10-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.